Dassault Systèmes Intensifies the MEDIDATA Commitment to Patient Experience with Investment in Click Therapeutics for Digital Therapeutics beyond Clinical Trials
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today announced its investment in Click Therapeutics, a leader in prescription digital therapeutics and software-enhanced drug therapies. The transaction advances Dassault Systèmes’ transformation of the patient experience in life sciences and healthcare through end-to end technology solutions used across the healthcare ecosystem. The transaction strengthens the existing relationship between Dassault Systèmes’ […]
Arbor Raises $74M Amid Genetic Medicine’s Funding Slump
Arbor Biotechnologies on Tuesday announced a new $74 million fundraise that comes as many of its peers in genetic medicine struggle to secure venture investment. The Series C round led by Arch Venture Partners and TCGX will help Arbor advanced its lead program into clinical testing. Arbor is developing the gene editing therapy, dubbed ABO-101, […]
Riding the AI Wave in Medical Imaging: Navigating Adoption Hurdles, Disruption, and Scaling Success
In the current AI landscape dominated by headlines about Large Language Models (LLMs) like GPT-4 and companies like DeepSeek, it’s crucial to recognize that artificial intelligence encompasses a far broader spectrum of applications and technologies. While generative AI and chatbots capture public imagination, the healthcare industry, particularly medical imaging, leverages AI in ways that are […]
VitalConnect, Inc. Secures $100 Million in Financing
VitalConnect®, Inc., a leader in biosensor technology, specializing in ambulatory cardiac monitoring, today announced the closing of $100 million in financing through a combination of equity and debt capital. The equity financing was led by new investor Ally Bridge Group, with significant participation from the Company’s existing investors, including EW Healthcare Partners, MVM and Revelation […]
Crown Laboratories Completes Acquisition of Revance Therapeutics
Crown Laboratories, Inc. (“Crown”), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings. Jeff Bedard, Founder and Chief Executive […]
Discounts and the Impact of Shareholder Rights in Private Market Secondaries
Revelation Partners is commonly asked what our typical discount is. There is no “typical” discount, nor is discount a key driver of pricing. We have closed transactions at a premium to recent marks, and we have also closed transactions at discounts >50%. Discounts in secondary market transactions are not inputs but rather outputs of a […]
The Trump Administration’s Impact on Healthcare: A 2025 Outlook
With the 2024 election results finally in, it’s time to look ahead at the outlook for the healthcare industry under the new administration. We connected with Marwood Group, a leading healthcare advisory firm, who gave us the scoop on what we can expect under a Trump administration and Republican controlled Congress. Marwood’s Jennifer Meyers and […]
An Overview of Secondary Transactions – For Healthcare Companies
In this white paper, we cover: Watch a short video on what differentiates our secondary approach:
Stock Option Liquidity: A Guide for Private Company Employees
In this white paper, we cover: Watch a short video on this topic:
Navigating the Wave of Digital Disruptors in Behavioral Health
Investment in digital behavioral health companies has surged in recent years, driven by rising demand and favorable regulatory changes. We define this sector as tech-enabled practices who offer therapy, psychiatry, substance use disorder (“SUD”), and other behavioral health services. Typically, these services are offered through a telehealth platform but may also include in-person sessions or […]